137 related articles for article (PubMed ID: 33509639)
1. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
Tjota MY; Segal J; Stadler WM; Antic T
Pathology; 2021 Oct; 53(6):790-793. PubMed ID: 33509639
[No Abstract] [Full Text] [Related]
2. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
3. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss.
Kapur P; Gao M; Zhong H; Rakheja D; Cai Q; Pedrosa I; Margulis V; Xu L; Kinch L; Brugarolas J
Adv Anat Pathol; 2021 Jul; 28(4):251-257. PubMed ID: 34009776
[TBL] [Abstract][Full Text] [Related]
5. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
6. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
7. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
8. Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma.
Apanovich NV; Peters MV; Apanovich PV; Markova AS; Kamolov BS; Matveev VB; Karpukhin AV
Bull Exp Biol Med; 2018 Dec; 166(2):257-259. PubMed ID: 30488209
[TBL] [Abstract][Full Text] [Related]
9. Genetics of renal cancer: focus on MTOR.
Ghosh AP; Sudarshan S
Aging (Albany NY); 2016 Mar; 8(3):421-2. PubMed ID: 27017990
[No Abstract] [Full Text] [Related]
10. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy.
Caliò A; Marletta S; Settanni G; Rizzo M; Gobbo S; Pedron S; Stefanizzi L; Munari E; Brunelli M; Marcolini L; Pesci A; Fratoni S; Pierconti F; Raspollini MR; Marchetti A; Doglioni C; Amin MB; Porta C; Martignoni G
Virchows Arch; 2023 Dec; 483(6):821-833. PubMed ID: 37938323
[TBL] [Abstract][Full Text] [Related]
11. mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter.
Roldan-Romero JM; Rodríguez-Moreno JF; García-Donás J; Rodríguez-Antona C
Clin Cancer Res; 2017 Sep; 23(17):5320. PubMed ID: 28864728
[No Abstract] [Full Text] [Related]
12. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
13. Renal cell metastases versus liver hemangioma.
Mydlo JH; Shore N; Herr HW
Urology; 1991 Mar; 37(3):257-9. PubMed ID: 2000686
[TBL] [Abstract][Full Text] [Related]
14. MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway.
Fu JH; Yang S; Nan CJ; Zhou CC; Lu DQ; Li S; Mu HQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):351-357. PubMed ID: 29424922
[TBL] [Abstract][Full Text] [Related]
15. A high-grade renal cell carcinoma with Somatic BRCA2 mutation.
Kong Q; Gagan J; Zhou M
Pathol Int; 2019 Jul; 69(7):432-433. PubMed ID: 31237028
[No Abstract] [Full Text] [Related]
16. A rare cause of large liver cysts.
Moons LG; Wolfhagen FH; Beukers R; de Man RA; van Leenders GJ; van Buuren HR
Am J Gastroenterol; 2009 Apr; 104(4):1056-8. PubMed ID: 19293785
[No Abstract] [Full Text] [Related]
17. Stimulator of interferon genes (STING) immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney.
Caliò A; Brunelli M; Gobbo S; Pedron S; Segala D; Argani P; Martignoni G
Pathology; 2021 Aug; 53(5):579-585. PubMed ID: 33461798
[TBL] [Abstract][Full Text] [Related]
18. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.
Maiti A; Brown RE; Corn PG; Murthy R; Ganeshan DM; Tsimberidou AM; Subbiah V
Clin Genitourin Cancer; 2016 Apr; 14(2):e187-93. PubMed ID: 26684814
[No Abstract] [Full Text] [Related]
20. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
